Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE versus NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE versus NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
DROSPIRENONE vs NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Spironolactone analog that antagonizes aldosterone at the mineralocorticoid receptor, leading to increased sodium and water excretion and potassium retention. Also has antiandrogenic activity by blocking androgen receptors and decreasing ovarian androgen production via inhibition of gonadotropin release.
Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary axis, further suppressing ovulation and altering cervical mucus and endometrial lining. Ferrous fumarate is an iron supplement for replacement of menstrual iron loss.
3 mg orally once daily.
One tablet (norethindrone 1 mg, ethinyl estradiol 10 mcg, and ferrous fumarate 75 mg) orally once daily at the same time each day for 28 consecutive days, starting on day 1 of menstrual cycle.
None Documented
None Documented
Clinical Note
moderateDrospirenone + Benzydamine
"Drospirenone may increase the hyperkalemic activities of Benzydamine."
Clinical Note
moderateDrospirenone + Droxicam
"Drospirenone may increase the hyperkalemic activities of Droxicam."
Clinical Note
moderateDrospirenone + Loxoprofen
"Drospirenone may increase the hyperkalemic activities of Loxoprofen."
Clinical Note
moderateDrospirenone + Clonixin
"Drospirenone may increase the hyperkalemic activities of Clonixin."
Terminal elimination half-life: ~30-35 hours (range 25-40 h); significant clinical accumulation occurs after repeated dosing, requiring 10-14 days to reach steady state.
Norethindrone: 5-8 hours (terminal). Ethinyl estradiol: 13-27 hours (terminal). Clinical context: dosing interval is 24 hours based on ethinyl estradiol half-life.
Renal: ~50% (as metabolites; <10% unchanged); Fecal: ~40-50% (as metabolites; bile-mediated); Urinary and fecal elimination account for >95% of an oral dose.
Norethindrone: ~80% renal (as glucuronide and sulfate conjugates), ~20% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal via enterohepatic recirculation. Ferrous fumarate: iron is absorbed and incorporated; excess excreted in feces as unabsorbed.
Category C
Category D/X
Progestin
Progestin